• Sunday, December 4, 2022 @ 12:00 am

Basilea is well on track to deliver on its new strategy to become a pure-play anti-invectives R&D company with sustainable profits from 2023 onwards. Currently, revenues are primarily driven by Cresemba. Zevtera’s revenues should get a considerable boost upon launch in the lucrative US market.

Key catalysts include:

1. Cresemba approval in Japan (Q4 2022)
2. Repayment 2022 convertible bond (December 2022)
3. US filing of Zevtera for severe bacterial infections (around year-end 2022)

Basilea Valuation Report

You may also be interested in